Search Within

Saad Zafar Usmani

  1. "Value in Health"
Formats
  1. Meeting Abstract (5)
Years
  1. 2023 (4)
  2. 2022 (1)
Publications
  1. Value in Health (5)
Publishers
  1. Elsevier Science, Inc. (5)

Results (5)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Comparative effectiveness of teclistamab versus real-world physician's choice of therapy (RWPC) for patients with triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM)
    Meeting Abstract

    Krishnan, A.; Nooka, A.; Chari, A.; Garfall, A. L.; Martin, T.; Nair, S.; Lin, X.; Qi, K.; Londhe, A.; Pei, L.; more...
    Value in Health (2023)

    Fulltext@MSK | Save
  • Matching-adjusted indirect treatment comparison (MAIC) of teclistamab versus selinexor-dexamethasone for the treatment of patients with triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM)
    Meeting Abstract

    Moreau, P.; Usmani, S. Z.; van de Donk, N. W. C. J.; Garfall, A. L.; Delforge, M.; Oriol, A.; Nooka, A.; Rosiñol, L.; Bahlis, N.; Rodriguez Otero, P.; more...
    Value in Health (2023)

    Fulltext@MSK | Save
  • Matching-adjusted indirect treatment comparison (MAIC) of teclistamab vs belantamab mafodotin for the treatment of patients with triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM)
    Meeting Abstract

    Moreau, P.; Usmani, S. Z.; van de Donk, N. W. C. J.; Garfall, A. L.; Delforge, M.; Oriol, A.; Nooka, A.; Rosiñol, L.; Bahlis, N.; Otero, P. R.; more...
    Value in Health (2023)

    Fulltext@MSK | Save
  • Adjusted comparison of teclistamab versus real-world physician's choice (RWPC) of therapy in patients with triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM)
    Meeting Abstract

    Mateos, M. V.; Chari, A.; Usmani, S. Z.; Goldschmidt, H.; Weisel, K.; Qi, K.; Londhe, A.; Nair, S.; Lin, X.; Pei, L.; more...
    Value in Health (2023)

    Fulltext@MSK | Save
  • Use of cost per responder models for CAR-T therapies in relapsed or refractory multiple myeloma
    Meeting Abstract

    Martin, T.; Usmani, S. Z.; Joseph, N.; Crivera, C.; Valluri, S.; Jackson, C. C.; Cohen, L.; Singh, S.; Jagannath, S.
    Value in Health (2022)

    Fulltext@MSK | Save